In TODAY.com’s Expert Tip of the Day, a doctor explains why patients with early, slow-growing prostate cancer may be able to ...

With active surveillance, the care team closely watches the cancer rather than starting treatment. This can include PSA ...

Lu-177 vipivotide tetraxetan shifted from post-taxane mCRPC to pre-chemotherapy mCRPC and then metastatic hormone-sensitive ...

As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about navigating treatment option in prostate cancer. Advancements in prostate ...

Prostate cancer screening, test interpretation and treatment decisions can be complex, particularly as new approaches to care ...

Researchers have found a potential way to attack prostate cancers that evade treatment by changing their cellular identity.

Q: Recently, a 47-year-old asymptomatic patient had a random prostate-specific antigen (PSA) level of 5.32 ng/mL. A repeat assay the following day was 6.10. All previous PSAs over a seven-year period ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer be controlled with hormone therapy. Even in such situations, effective ...

Despite medical advances and increased awareness campaigns, many men continue postponing essential prostate treatment. Health care providers identify several key factors contributing to these ...

Today, a patient diagnosed with advanced prostate cancer has options. Doctors can offer a suite of androgen-suppressing drugs to extend his life. There are genetic tests that can show whether he’s a ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...